Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial
- PMID: 37732816
- DOI: 10.14309/ajg.0000000000002499
Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial
Abstract
Introduction: Successful biliary drainage and antibiotics are the mainstays of therapy in management of patients with acute cholangitis. However, the duration of antibiotic therapy after successful biliary drainage has not been prospectively evaluated. We conducted a single-center, randomized, noninferiority trial to compare short duration of antibiotic therapy with conventional duration of antibiotic therapy in patients with moderate or severe cholangitis.
Methods: Consecutive patients were screened for the inclusion criteria and randomized into either conventional duration (CD) group (8 days) or short duration (SD) group (4 days) of antibiotic therapy. The primary outcome was clinical cure (absence of recurrence of cholangitis at day 30 and >50% reduction of bilirubin at day 15). Secondary outcomes were total days of antibiotic therapy and hospitalization within 30 days, antibiotic-related adverse events, and all-cause mortality at day 30.
Results: The study included 120 patients (the mean age was 55.85 ± 13.52 years, and 50% were male patients). Of them, 51.7% patients had malignant etiology and 76.7% patients had moderate cholangitis. Clinical cure was seen in 79.66% (95% confidence interval, 67.58%-88.12%) patients in the CD group and 77.97% (95% confidence interval, 65.74%-86.78%) patients in the SD group ( P = 0.822). On multivariate analysis, malignant etiology and hypotension at presentation were associated with lower clinical cure. Total duration of antibiotics required postintervention was lower in the SD group (8.58 ± 1.92 and 4.75 ± 2.32 days; P < 0.001). Duration of hospitalization and mortality were similar in both the groups.
Discussion: Short duration of antibiotics is noninferior to conventional duration in patients with moderate-to-severe cholangitis in terms of clinical cure, recurrence of cholangitis, and overall mortality.
Copyright © 2023 by The American College of Gastroenterology.
Comment in
-
Caution on Interpretation of Noninferiority Trial Results.Am J Gastroenterol. 2024 Jul 1;119(7):1438. doi: 10.14309/ajg.0000000000002763. Epub 2024 Apr 26. Am J Gastroenterol. 2024. PMID: 38666669 No abstract available.
References
-
- Kiriyama S, Takada T, Hwang TL, et al. Clinical application and verification of the TG13 diagnostic and severity grading criteria for acute cholangitis: An international multicenter observational study. J Hepatobiliary Pancreat Sci 2017;24(6):329–37.
-
- Mohan R, Lynn Goh WeiS, Tan GW, et al. Validation of Tokyo guidelines 2007 and Tokyo guidelines 2013/2018 criteria for acute cholangitis and predictors of in-hospital mortality. Visc Med 2021;37(5):434–42.
-
- Lipsett PA, Pitt HA. Acute cholangitis. Surg Clin North Am 1990;70(6):1297–312.
-
- Mohan R, Goh SWL, Tan G, et al. Validation of TG07 and TG13/TG18 criteria for acute cholangitis and predictors of in-hospital mortality in patients over 80 years old. Clin Exp Hepatol 2021;7(4):396–405.
-
- Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: Antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 2018;25(1):3–16.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical